Identification

Generic Name
Methantheline
DrugBank Accession Number
DB00940
Background

Methantheline is a synthetic antispasmodic. Antispasmodics are used to relieve cramps or spasms of the stomach, intestines, and bladder. Methantheline is used to treat intestine or stomach ulcers (peptic ulcer disease), intestine problems (irritable bowel syndrome), pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, or urinary problems (reflex neurogenic bladder in children).

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 340.436
Monoisotopic: 340.191268703
Chemical Formula
C21H26NO3
Synonyms
  • Methantheline
  • Methantheline cation
  • Methantheline ion
  • Methanthelinium
  • Methanthelinum
External IDs
  • MTB 51

Pharmacology

Indication

For the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline inhibits muscarinic actions at postganglionic parasympathetic neuroeffector sites.

Mechanism of action

Methantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These postganglionic receptor sites are present in the autonomic effector cells of the smooth muscle, cardiac muscle, sinoatrial and atrioventricular nodes, and exocrine glands. Depending on the dose, anticholinergics may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant action on the bile ducts and gallbladder.

TargetActionsOrganism
UMuscarinic acetylcholine receptor M1
antagonist
Humans
AHistamine H2 receptor
antagonist
Humans
UMuscarinic acetylcholine receptor M2Not AvailableHumans
UMuscarinic acetylcholine receptor M3Not AvailableHumans
UMuscarinic acetylcholine receptor M4Not AvailableHumans
UMuscarinic acetylcholine receptor M5Not AvailableHumans
Absorption

Rapidly absorbed.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic, by enzymatic hydrolysis.

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Symptoms of overdose: blurred vision (continuing) or changes in near vision, clumsiness or unsteadiness, confusion, convulsions, difficulty in breathing, muscle weakness (severe), or tiredness (severe), dizziness, drowsiness (severe), dryness of mouth, nose, or throat (severe), fast heartbeat, fever, hallucinations, slurred speech, unusual excitement, nervousness, restlessness, or irritability, unusual warmth, dryness, and flushing of skin.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-Benzodiazepine1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
AcetazolamideAcetazolamide may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
AcetophenazineAcetophenazine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
AclidiniumThe risk or severity of adverse effects can be increased when Methantheline is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Methantheline.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
AlfentanilThe risk or severity of adverse effects can be increased when Methantheline is combined with Alfentanil.
AlimemazineAlimemazine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Methantheline.
AlmotriptanAlmotriptan may increase the central nervous system depressant (CNS depressant) activities of Methantheline.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Methantheline bromide090519SAPF53-46-3PQMWYJDJHJQZDE-UHFFFAOYSA-M
International/Other Brands
Banthine / Vagantin

Categories

ATC Codes
A03AB07 — Methantheline
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as xanthenes. These are polycyclic aromatic compounds containing a xanthene moiety, which consists of two benzene rings joined to each other by a pyran ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
Xanthenes
Alternative Parents
Diarylethers / Benzenoids / Tetraalkylammonium salts / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic salts / Organic oxides / Hydrocarbon derivatives
show 3 more
Substituents
Amine / Aromatic heteropolycyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diaryl ether / Ether / Hydrocarbon derivative / Monocarboxylic acid or derivatives
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
xanthenes (CHEBI:6817)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
36EI79TX7I
CAS number
5818-17-7
InChI Key
GZHFODJQISUKAY-UHFFFAOYSA-N
InChI
InChI=1S/C21H26NO3/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20/h6-13,20H,4-5,14-15H2,1-3H3/q+1
IUPAC Name
diethyl(methyl)[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium
SMILES
CC[N+](C)(CC)CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12

References

General References
Not Available
Human Metabolome Database
HMDB0015075
KEGG Compound
C07849
PubChem Compound
4097
PubChem Substance
46505807
ChemSpider
3955
RxNav
6821
ChEBI
6817
ChEMBL
CHEMBL1201264
ZINC
ZINC000001530932
Therapeutic Targets Database
DAP001109
PharmGKB
PA164747037
Wikipedia
Methantheline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceNeurogenic Bladder Dysfunction1

Pharmacoeconomics

Manufacturers
  • Shire development inc
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000132 mg/mLALOGPS
logP0.5ALOGPS
logP-0.47ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)18.1ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area35.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity110.42 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption-0.9075
Blood Brain Barrier+0.9411
Caco-2 permeable+0.648
P-glycoprotein substrateSubstrate0.8327
P-glycoprotein inhibitor INon-inhibitor0.817
P-glycoprotein inhibitor IINon-inhibitor0.5977
Renal organic cation transporterNon-inhibitor0.5359
CYP450 2C9 substrateNon-substrate0.8214
CYP450 2D6 substrateNon-substrate0.599
CYP450 3A4 substrateSubstrate0.6801
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8476
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5637
Ames testNon AMES toxic0.8371
CarcinogenicityNon-carcinogens0.7407
BiodegradationNot ready biodegradable0.5863
Rat acute toxicity2.7675 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7426
hERG inhibition (predictor II)Inhibitor0.7318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Irmen M, Holze J, Bodefeld T, Trankle C: Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1037-1052. doi: 10.1007/s00210-018-1525-1. Epub 2018 Jun 24. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and diff...
Gene Name
HRH2
Uniprot ID
P25021
Uniprot Name
Histamine H2 receptor
Molecular Weight
40097.65 Da
References
  1. Hough LB, Barker LA: Histamine H2-receptor antagonism by propantheline and derivatives. J Pharmacol Exp Ther. 1981 Nov;219(2):453-8. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov;100(5):987-1006. doi: 10.1111/j.1464-410X.2007.07205.x. [Article]
  2. Irmen M, Holze J, Bodefeld T, Trankle C: Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1037-1052. doi: 10.1007/s00210-018-1525-1. Epub 2018 Jun 24. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Abrams P, Andersson KE: Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov;100(5):987-1006. doi: 10.1111/j.1464-410X.2007.07205.x. [Article]
  2. Irmen M, Holze J, Bodefeld T, Trankle C: Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1037-1052. doi: 10.1007/s00210-018-1525-1. Epub 2018 Jun 24. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Irmen M, Holze J, Bodefeld T, Trankle C: Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1037-1052. doi: 10.1007/s00210-018-1525-1. Epub 2018 Jun 24. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Irmen M, Holze J, Bodefeld T, Trankle C: Characterization of methanthelinium binding and function at human M1-M5 muscarinic acetylcholine receptors. Naunyn Schmiedebergs Arch Pharmacol. 2018 Oct;391(10):1037-1052. doi: 10.1007/s00210-018-1525-1. Epub 2018 Jun 24. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Hallek M, Szinicz L: Methantheline improves the reactivation by HI 6 of human erythrocyte acetylcholinesterase inhibited by soman in vitro. Arch Toxicol. 1995;70(1):16-9. doi: 10.1007/s002040050243. [Article]

Drug created at June 13, 2005 13:24 / Updated at October 09, 2021 02:47